




Government of **Western Australia**
North Metropolitan Health Service
Sir Charles Gairdner Osborne Park Health Care Group



Research report

Sir Charles Gairdner Osborne Park Health Care Group 2024 - 2025



Executive summary

This report demonstrates the valuable contribution the SCGOPHCG Department of Research makes in supporting the research community at both sites.

SCGOPHCG places great emphasis on research as a cornerstone of providing healthcare grounded in evidence. This approach is pivotal to achieving better health outcomes for our patients and their families, as well as our dedicated staff, the broader community we serve and our organisation as a whole.

We actively cultivate a culture that values and promotes engagement in research, fostering high-quality research through collaborations with international, national and local partners. These collaborations involve consumers, healthcare providers, the Charlies Foundation for Research, research institutes and universities.

Through these partnerships, our goal is to enhance health and wellbeing by advancing interdisciplinary healthcare, generating new knowledge and fostering the exchange and growth of skills and expertise.

SCGOPHCG Research Strategy 2024-2034

We are focused on strengthening our research program to grow capability, attract funding, and drive transformative health solutions for better outcomes as a key priority in our strategic plan.

To align with the WA Health and Medical Research Strategy 2023-2033 vision of becoming a collaborative, consumer-driven ecosystem that leads impactful research, our research strategy is focused on:



Capacity building

- Develop and strengthen research skills and resources
- Grow relationships across research stakeholders and the community
- Build a purpose-driven and positive research culture
- Streamline processes from idea to impact
- Develop expertise in leading research initiatives and establish a respected global reputation.



Knowledge generation, translation and implementation

- Co-design research priorities
- Generate and translate knowledge that drives sustainable and economically viable best practice
- Evaluate outcomes and dissemination of knowledge.



Research impact

- Demonstrate growth in research knowledge, capacity and health and societal benefits
- Assess the organisational return on investment of research efforts
- Track research impact to align outcomes with research priorities.



Infrastructure

- Grow access to research education, resources, and support
- Integrate business support services to promote efficiency and assess performance
- Build researcher communities of practice, research networks and collaborative zones.

The main research strategic priority for 2025 is a gap analysis to strengthen SCGOPHCG's ongoing accreditation readiness against the National Clinical Trials Governance Framework.

The Department of Research will work as part of NMHS to progress the Research and Innovation Strategy, which includes wide consultation, testing, validation and implementation for an estimated launch in November 2025.

An additional focus will be strengthening research capabilities with strategic reinvestment of Research Infrastructure Support grant funding to support the sustainable growth of our research environment and infrastructure.



Research activity

A total of 356 projects were active within the reporting period. Of these 205 (58%) went through a National Mutual Acceptance (NMA) ethics process, and 151 (42%) were approved via a non-NMA ethics process.

These projects were across three main risk types: 'minimal', 'low', and 'more than low risk'. The majority of research active projects (n=247, 69%) were considered 'more than low risk'. The most research was cancer related (n=215, 60%) and the majority of allied health-led research was undertaken at OPH (n=13, 54%).

There were 189 (53%) clinical trials underway in this reporting period. Just over half were commercially sponsored (n=98, 52%), with the majority being Phase III trials (n=65). The rest of the projects (n=167, 47%) were considered non-clinical trials; however, 12 (7%) were commercially sponsored.


In the 2024-2025 reporting period, 5,057 participants were expected to be recruited across all the active studies. The actual recruitment of participants in this reporting period was 9,041.



9,041
participants



189
clinical trials



356
active projects



60%
of research was
cancer related

Artistic conception of active synaptic transmission in the human brain

New research authorised 1 July 2024 – 30 June 2025

PRN	Title
RG00000006767	17β-Hydroxysteroid Dehydrogenase type 13 Minimization for the treatment of NASH (HORIZON): A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of GSK4532990 in Adults with Nonalcoholic Steatohepatitis
RG00000006705	ARASTEP: A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer
RG00000006484	Can Molecular Testing in Early Stage Non-Small Cell Lung Cancer Identify Patients at Risk of Recurrence Post Resection?
RG00000006749	RAMP 301: A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
RG00000003406	Neo-antigen immune response in tumour draining lymph nodes, non-tumour draining lymph nodes and peripheral blood in patients with non-small cell lung cancer.


PRN	Title
RG00000006259	A Phase II, Multicenter, Double Blinded, Randomized, Placebo Controlled, Parallel-Group, Single-Dose Study to Determine the Safety, Preliminary Efficacy, and Pharmacokinetics of ARG-007 in Acute Ischemic Stroke Patients
RG00000004629	MajesTEC-7 - A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination with Daratumumab SC and Lenalidomide (Tal-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy
RG00000006121	Can Intracardiac Echocardiography Catheter IVUS assessment of inferior vena cava / retroperitoneal tumour interface predict the need for caval replacement and ECMO during tumour resection?
RG00000006288	The Australia and New Zealand Multicentre Upper Gastrointestinal Endoscopic Tissue Resection Study

PRN	Title
RG00000001379	MRDR: Myeloma and Related Diseases Registry
RG00000007041	Social Anxiety Disorder Program Evaluation In Community Mental Health
RG00000006846	Detecting dysplastic lesions in Barrett's esophagus using artificial intelligence (EMBARC)
RG00000006546	Oncogenic Drivers in Advanced Squamous Non-Small-Cell Lung Cancer: a real-world assessment.
RG00000006680	ASPIRE - Australian Particle Therapy Clinical Quality Registry
RG00000006672	Multicentre, adaptive, double-blind, three-arm, placebo-controlled, noninferiority trial examining antimicrobial prophylaxis duration in cardiac surgery
RG00000006383	A Phase 2 Randomised Controlled Trial of Sodium Selenate as a Disease Modifying Treatment for Chronic Drug-resistant Temporal Lobe Epilepsy
RG00000006736	SOUNDTRACK-F1 - A Phase III, Multicentre, Randomised, Open-label Study to Compare the Efficacy and Safety of AZD0486 plus Rituximab versus Chemotherapy plus Rituximab in Previously Untreated Participants with Follicular Lymphoma

PRN	Title
RG00000005836	Referral practices for people at-risk of Huntington's disease with psychiatric presentation to Western Australian public health services
RG00000006443	Minimising Oral Corticosteroid use in Asthma using Treatable Traits
RG00000006729	Mobile-based Pupillometry for early diagnosis of Alzheimer's Disease
RG00000005900	A randomized, placebo-controlled, double-blind, multi-center, phase III trial to assess the efficacy and safety of trimodulin (BT588) in adult hospitalized subjects with severe community-acquired pneumonia (sCAP)
RG00000006962	Access to optimal ovarian cancer care: An investigation of clinical trials awareness and participation
RG00000006483	Evaluation of geographic variations in appendectomy outcomes within Western Australia assessing the impact of surgical wait times and rate of negative appendectomies in both urban and rural locations statewide

PRN	Title
RG00000006880	TroFuse 020: A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer
RG00000006836	Development, implementation, and evaluation of strategies to support nurse middle managers.
RG00000005086	The sedentary behaviour and physical activity patterns of adults in hospital: A prospective observational study
RG00000006053	A pilot study of the utility of Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) imaging in locoregional response prediction and survival in hepatocellular carcinoma (HCC)
RG00000006909	Neck CT-angiogram findings in non-fatal strangulation: a retrospective 10-year review to determine incidence of vascular, bony and soft tissue injuries.
RG00000006611	Treatment Package Time in Cutaneous Squamous Cell and Basal Cell Carcinomas

PRN	Title
RG00000006947	KRT-232-115 A phase 3, randomized, double-blind, add-on study evaluating the safety and efficacy of Navtemadlin plus Ruxolitinib vs placebo plus Ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis who have a suboptimal response to Ruxolitinib
RG00000006914	Exploring the accuracy of hepatocellular carcinoma predictive models in MASLD: a retrospective cohort study
RG00000006897	Can an early ED allied health service improve patient and system outcomes for frail older adults? A before and after intervention study
RG00000007058	First in Human Study of Middle Meningeal Artery Embolisation with the Arsenal Medical NeoCast Embolic System for the Treatment
RG00000006797	Anti-NMDA Receptor Encephalitis in Western Australia
RG00000006619	OPERATE: Older Persons Early Recognition, Access and Treatment in Emergencies - NMHS Intervention Evaluation





PRN	Title
RG0000007038	DESTINY BTC-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer (DESTINY BTC01)
RG0000006671	A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2-arm study to investigate the safety and immunogenicity of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers
RG0000006889	AK-US-001-0106: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH)
RG0000006218	Real-world multicentre study of efficacy and safety of Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma (HCC)

PRN	Title
RG0000006957	A phase 3 open-label, randomized, controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable, metastatic/ recurrent head and neck squamous cell carcinoma
RG0000007109	The Australian experience with avacopan in vasculitis
RG0000007163	Designing and implementing novel health informatics approaches to improve outcomes for people with mild TBI across Australia (AUS-mTBI APP)
RG0000006800	The effectiveness of Silver Fluoride and Teledentistry in managing and preventing childhood dental decay among Aboriginal children in remote communities
RG0000007077	ePAD electronic Prostate Cancer Australian Database: Analyzing Treatment Patterns and Outcomes from Real-World Patients with Advanced Prostate Cancer
RG0000006704	TRACIE: TRodelvy use in AdvanCed TrIple Negative BrEaSt Cancer in Australia

PRN	Title
RG0000007129	CASPER: Colchicine After Stroke to Prevent Event Recurrence. A randomised trial to evaluate the efficacy of oral Colchicine in high risk patients with atherosclerosis-associated inflammation post stroke.
RG0000007011	An investigation of the prevalence and risks of Outpatient Parenteral Antimicrobial Therapy (OPAT) in patients undergoing long-term treatment
RG0000006434	Does Collective Singing Improve Health Outcomes in Inpatient Rehabilitation? An Investigation into Psychological Wellbeing and Pain perception
RG0000006942	Can early occupational therapy reduce lymphoedema in patients following head and neck cancer treatment?
RG0000006734	An implementation-effectiveness trial investigating feasibility, safety and efficacy of Best pRacticE guideline cAre physioTHERapy with addition of protocolised ventilator hyperinflation on patient-important outcomes for critically ill adults intUbated and ventilated with Pneumonia. (BREATHE UP)
RG0000007023	CML14 /ASCENDANCE- Asciminib evaluation in newly diagnosed CML with Dasatinib to augment response in complex genomic etiology

PRN	Title
RG0000007260	Improving pain assessment for patients with cognitive impairment in the emergency department
RG0000006992	AusNanoMED: Australasian nanoparticle-mediated magnetically enhanced diffusion for ischemic stroke
RG0000003337	The Western Australian Biologics and Immunosuppressant Registry for IBD
RG0000005300	Upper Gastrointestinal Cancer Registry
RG0000006882	CHONQUER: A Phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib in participants ≥18 years of age with locally advanced or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1 systemic treatment regimen
RG0000006136	SMART exercise intervention for people recently diagnosed with breast cancer
RG0000006676	Australian and New Zealand Fragility Fracture Registry

PRN	Title
RG0000006401	ALLG NHL39 / NLG-LBC7 (POLAR BEAR): R-MINI-CHOP versus R-MINI-CHP in combination with polatuzumab-vedotin, as primary treatment for patients with diffuse large B-cell lymphoma, ≥80 years, or frail ≥75 years – an open label randomized Nordic Lymphoma Group phase III trial
RG0000007086	Residual Kidney Function Preservation in Patients Undergoing Maintenance Haemodialysis: a Survey to Explore the Practice Challenges Faced by Renal Clinicians
RG0000006556	The ENhAnCe trial: Evaluating Neuropsychological Assessment to enhance Clinical outcomes for individuals with brain conditions
RG0000007419	Forced Oscillation Technique in Pneumothorax (PneumoFOT) Study: Respiratory mechanics in patients with pneumothorax
RG0000007209	Tissue Repository of Airway Cancers for Knowledge Expansion of Resistance
RG0000007364	Exploring nurse preceptors' experiences of precepting newly qualified nurses who do not meet performance expectations within the clinical setting

PRN	Title
RG0000007153	PRISM-MEL-301: A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma
RG0000007208	LUMOS2: Low & Anaplastic Grade Glioma Umbrella Study of Molecular Guided Therapies
RG0000007411	A qualitative exploration of physician trainees' experiences with strategies that support wellbeing during high stakes examinations and the impacts on learning and examination performance.
RG0000007446	Outcomes and prognostic markers in patients with chronic liver disease
RG0000007233	A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects with Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab


PRN	Title
RG0000007229	SNDX-5613-0708 - A Phase 1, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of SNDX-5613 in Combination with Intensive Chemotherapy in Participants with Newly Diagnosed Acute Myeloid Leukemias Harboring Alterations in Lysine-specific Methyltransferase 2A (KMT2A/MLL), Nucleophosmin 1 (NPM1), and Nucleoporin 98 (NUP98) Genes
RG00000006900	The safety of short-term dialysis catheter positioning within the right heart and great thoracic vessels. A mixed methods study.
RG00000007194	HD11 ALLG/CCTG - A Randomized Phase II Study of Pembrolizumab and Brentuximab Vedotin Versus GDP, followed by High Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Classical Hodgkin Lymphoma
RG00000007101	PyramIDH - A phase 3, multicenter, open label, randomized, non-comparative two arm study of ivosidenib (IVO) monotherapy and azacitidine (AZA) monotherapy in adult patients with hypomethylating agent (HMA) naive myelodysplastic syndromes (MDS) with an isocitrate dehydrogenase-1 (IDH1) mutation

PRN	Title
RG00000007191	HORIZON 02: A Phase I-III, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients with Resectable Stage I-III Non-Small Cell Lung Cancer, Selected According to Biomarker Status
RG00000007179	iMMagine-3 - A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma
RG00000005953	Sugammadex, neostigmine and postoperative pulmonary complications: The SNaPP Study.
RG00000007312	Exploring the personal experiences of nurses and midwives transitioning to menopause in the workplace.
RG00000007400	Assessing the real-world outcomes of patients with early-stage unfavourable Hodgkin Lymphoma treated with 2+2
RG00000007093	Prioritising early hand therapy to rationalise surgical resources: Can access to outpatient hand therapy reduce surgical waitlists and improve clinical outcomes?

PRN	Title
RG00000006991	A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Intrathecally Administered ALN-APP in Patients with Cerebral Amyloid Angiopathy (CAA)
RG00000006999	Pioneering innovative, sustainable and scalable solutions to improve the utilisation of pulmonary rehabilitation programs in Perth, Western Australia
RG00000006302	AK-US-001-0105: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Non-Cirrhotic Non-alcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
RG00000007228	90189892AML1001 - A Phase 1, First-in-Human, Dose Escalation Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
RG00000007212	VELOCITY-HNSCC: A Phase 2 Platform Study of Novel Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma. Substudy-01: A Phase 2 Study of Novel Combination Therapies in Participants With Previously Untreated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status


PRN	Title
RG00000007103	ASCENT-GYN-01: A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy
RG00000004713	Methylene Blue Assessment of Gain In Cardiac Surgery trial (MAGIC). A protocol for a multicentre, parallel group, single-blind, randomised clinical trial, incorporating a nested vanguard pilot phase pilot phase to compare the use of methylene blue vs placebo in post-operative cardiac surgery vasoplegia.
RG00000007471	Management of biochemical relapse in myeloma patients (AU and NZ)
RG00000007319	DYNASTY-Breast02: Phase 3, Randomized, Multi-center, Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET)
RG00000006968	Use of patient-derived cell models for preclinical assessment of the therapeutic efficacy of a novel ADPKD treatment

PRN	Title
RG00000007385	A Phase 2 Multicenter Study of TL-895 in Subjects with Relapsed/Refractory Myelofibrosis, Janus Kinase Inhibitor Intolerant Myelofibrosis, Janus Kinase Inhibitor Treatment Ineligible Myelofibrosis, or Indolent Systemic Mastocytosis
RG00000000930	Improve immuNologiCal assessmEnt to improve PaediaTric kidney transplantatIOn outcomes
RG00000006892	TRIVIA Study (Tissue repair gel in Venous Leg Ulcers in Australia/ NZ/America). A Phase 3 randomised, double-blind, study to elevate the efficacy, tolerability, and safety of TR987® 0.1% gel versus Standard of Care in the treatment of chronic venous insufficiency leg ulcers (VLU)
RG00000007121	RAINIER - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Povetacicept in Adults with Immunoglobulin A Nephropathy
RG00000007175	A prospective, Open-Label, Randomised, Phase 3 Trial of Acasunlimab (GEN1046) in Combination with Pembrolizumab Versus Docetaxel in Subjects with PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment with a PD-1/ PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06)



PRN	Title
RG00000007568	DESTINY-Endometrial01: An Open-Label, Sponsor-Blinded, Randomized, Controlled, Multicenter, Phase III Study of Trastuzumab Deruxtecan (T-DXd) Plus Rilvegostomig or Pembrolizumab vs Chemotherapy Plus Pembrolizumab as First-Line Therapy of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR), Primary Advanced or Recurrent Endometrial Cancer
RG00000005125	Clinical, Rehabilitation and Neuroimaging Investigation of Lateropulsion, Graviticeptive Neglect and Verticality Perception in Neurosurgical Patients with Brain Tumours: A Prospective Cohort Study.
RG00000007037	ADOPT-Lung: An international muticentre open-label randomised phase III trial evaluating the benefit of adding adjuvant durvalumab after neoadjuvant chemo-immunotherapy in stage IIB-IIIB (N2) resectable NSCLC.
RG00000005125	Clinical, Rehabilitation and Neuroimaging Investigation of Lateropulsion, Graviticeptive Neglect and Verticality Perception in Neurosurgical Patients with Brain Tumours: A Prospective Cohort Study.
RG00000007144	A phase 2, multicentre, randomised, placebo controlled clinical trial of dexmedetomidine as part of a sleep promotion bundle in adult intensive care units

PRN	Title
RG00000007547	The sedentary behaviour and physical activity patterns of older adults in hospital: A prospective randomised controlled trial using the SENS motion® system
RG00000007290	Prostate Cancer Outcomes Registry- Western Australia (PCOR-WA)
RG00000007550	Impact of induction chemotherapy and primary CNS prophylaxis on outcomes in high-grade B-cell lymphoma with MYC + BCL2 ± BCL6 rearrangements (HGBL-DH/TH) and high-grade B-cell lymphoma-NOS: an international multi-centre retrospective analysis



Grants and partnerships


The new coordinator grants and partnerships role, which began in September 2024, has supported researchers finding and applying for grants, as well as helping to administer the Charlies Foundation Research grants.

The Research Infrastructure Support (RIS) program supports the indirect and operational costs associated with research. This funding is provided by the Office of Medical Research and Innovation (OMRI). In 2024, \$198,618 was awarded and used to offset pilot positions – the coordinator grants and partnerships role and a coordinator research navigation role.

In May 2025, the RIS application resulted in \$848,743 being awarded to NMHS to support the provision of research facilities, equipment and services that meet specific grant guidelines.

The coordinator grants and partnerships has supported 35 grant applications across local, national and international grant funding schemes. This role has also helped 10 researchers with publications in peer-reviewed journals. Within this reporting period, the largest successful grant has been the FHRI Fund Enabling Scheme 2024-2025, with activity lead Clinical Professor Rajesh Thomas awarded \$1,250,000.

Our researchers secured a range of grants from the State Government, Charlies Foundation for Research and other sources in 2024-2025:



Acknowledgement of Country

We acknowledge the Noongar people as the traditional owners and custodians of the land on which we work, and pay respect to their Elders both past and present. North Metropolitan Health Service recognises, respects and values Aboriginal cultures as we walk a new path together.

SCGOPHCG Department of Research

📞 (08) 6457 6842

✉ scgh.researchmanager@health.wa.gov.au



<https://www.scgh.health.wa.gov.au/Research/Department-of-Research>

This document can be made available
in alternative formats on request.

Sir Charles Gairdner Hospital

📍 Hospital Ave, Nedlands WA 6009

📞 General enquiries (08) 6457 3333

📞 Hearing impaired (TTY) (08) 6457 3900

🌐 scgh.health.wa.gov.au

© North Metropolitan Health Service 2025

